<DOC>
	<DOCNO>NCT01092065</DOCNO>
	<brief_summary>This Phase IIb exploratory study design determine whether AFQ056 safe effective whether increase therapeutic window L-dopa patient whose control Parkinson 's Disease symptom limit development dyskinesia induce use L-dopa .</brief_summary>
	<brief_title>Efficacy Safety AFQ056 When Combined With Increased Doses L-dopa Parkinson 's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Dihydroxyphenylalanine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Outpatients Parkinson 's Disease ( PD ) , treat Ldopa , experience OFF time dyskinesia least three month Surgical treatment PD Cancer within past 5 year ( localized skin cancer prostate cancer effectively treat ) Advanced , severe unstable disease ( PD ) may interfere study outcome evaluation Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Drug-induced</keyword>
	<keyword>Levodopa</keyword>
	<keyword>L-dopa</keyword>
</DOC>